Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

LXRX – Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc.
LXRX
$0.8209
Name : Lexicon Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $298,132,800.00
EPSttm : -0.5
finviz dynamic chart for LXRX
Lexicon Pharmaceuticals, Inc.
$0.8209
11.66%
$0.1084

Float Short %

21.22

Margin Of Safety %

Put/Call OI Ratio

0.08

EPS Next Q Diff

-0.01

EPS Last/This Y

0.31

EPS This/Next Y

-0.03

Price

0.83

Target Price

2.92

Analyst Recom

2

Performance Q

136.16

Relative Volume

1.36

Beta

1.1

Ticker: LXRX




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02LXRX0.620.080.0828731
2025-06-03LXRX0.6320.080.0028726
2025-06-04LXRX0.66150.080.0228737
2025-06-05LXRX0.71650.080.0028792
2025-06-06LXRX0.76880.080.0028668
2025-06-09LXRX0.7410.080.0129243
2025-06-10LXRX0.69560.080.0229101
2025-06-11LXRX0.70070.080.0029364
2025-06-12LXRX0.69480.080.0329475
2025-06-13LXRX0.67820.080.0229477
2025-06-16LXRX0.66010.080.0429598
2025-06-17LXRX0.72060.080.0029730
2025-06-18LXRX0.7430.080.0229793
2025-06-20LXRX0.750.080.0030201
2025-06-23LXRX0.73110.080.0027413
2025-06-24LXRX0.77230.080.0028158
2025-06-25LXRX0.89070.070.0229155
2025-06-26LXRX0.92240.070.2530376
2025-06-27LXRX0.82990.080.0230546
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02LXRX0.6254.447.1-0.33
2025-06-03LXRX0.6354.443.8-0.33
2025-06-04LXRX0.6654.439.1-0.33
2025-06-05LXRX0.7254.430.2-0.33
2025-06-06LXRX0.7754.434.2-0.33
2025-06-09LXRX0.7554.451.8-0.33
2025-06-10LXRX0.7054.458.8-0.33
2025-06-11LXRX0.7054.447.1-0.33
2025-06-12LXRX0.7054.448.9-0.33
2025-06-13LXRX0.6854.451.5-0.33
2025-06-16LXRX0.6754.448.1-0.33
2025-06-17LXRX0.7254.431.8-0.33
2025-06-18LXRX0.7554.440.6-0.33
2025-06-20LXRX0.7554.445.9-0.33
2025-06-23LXRX0.7354.450.9-0.33
2025-06-24LXRX0.7754.438.1-0.33
2025-06-25LXRX0.9054.417.4-0.33
2025-06-26LXRX0.9254.442.4-0.33
2025-06-27LXRX0.8354.464.2-0.33
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02LXRX0.00-23.9424.30
2025-06-03LXRX0.00-23.9424.30
2025-06-04LXRX0.00-23.9424.30
2025-06-05LXRX0.00-23.9424.30
2025-06-06LXRX0.00-23.9424.30
2025-06-09LXRX0.00-23.9424.30
2025-06-10LXRX0.00-23.9424.30
2025-06-11LXRX0.00-23.9421.93
2025-06-12LXRX0.00-23.9421.93
2025-06-13LXRX0.00-23.9421.94
2025-06-16LXRX0.00-23.9421.94
2025-06-18LXRX0.00-23.9421.94
2025-06-20LXRX0.00-23.9421.94
2025-06-23LXRX0.00-23.9421.94
2025-06-24LXRX0.00-23.9421.94
2025-06-25LXRX0.00-23.9421.94
2025-06-26LXRX0.00-23.9421.22
2025-06-27LXRX0.00-23.9421.22
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

-0.07

Avg. EPS Est. Current Quarter

-0.08

Avg. EPS Est. Next Quarter

-0.08

Insider Transactions

Institutional Transactions

-23.94

Beta

1.1

Average Sales Estimate Current Quarter

4

Average Sales Estimate Next Quarter

4

Fair Value

Quality Score

37

Growth Score

35

Sentiment Score

50

Actual DrawDown %

91.4

Max Drawdown 5-Year %

-96.8

Target Price

2.92

P/E

Forward P/E

PEG

P/S

9.55

P/B

2.42

P/Free Cash Flow

EPS

-0.51

Average EPS Est. Cur. Y​

-0.33

EPS Next Y. (Est.)

-0.36

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-568.04

Relative Volume

1.36

Return on Equity vs Sector %

-168

Return on Equity vs Industry %

-150.2

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

64.2
Lexicon Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 103
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
stock quote shares LXRX – Lexicon Pharmaceuticals, Inc. Stock Price stock today
news today LXRX – Lexicon Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch LXRX – Lexicon Pharmaceuticals, Inc. yahoo finance google finance
stock history LXRX – Lexicon Pharmaceuticals, Inc. invest stock market
stock prices LXRX premarket after hours
ticker LXRX fair value insiders trading